Video clip on CeBIL Kick-Off Conference

Video clips from the CeBIL Kick-Off Conference: Innovation Gaps on Life Science Frontiers? From Antimicrobial Resistance & the Bad Bugs to New Uses, AI & the Black Box, which was held on Monday, 5 March 2018  at the University of Copenhagen, Ceremonial Hall (Festsalen).

Welcome and Introductory remarks

Timo Minssen, Professor, CeBIL Managing Director, Faculty of Law, University of Copenhagen (DK)

Introductory remarks:
Jacob Graff Nielsen, Professor, Dean of the Faculty of Law, University of Copenhagen (DK), Ulla Wewer, Professor, Dean of UCPH Health & Medical Sciences, University of Copenhagen (DK) and Lars Torup, Programme Manager at the Novo Nordisk Foundation (DK)

Study 1: Antimicrobial Resistance
Innovation and Antibiotic Development
Aaron S. Kesselheim, Assoc. Professor, Principal Investigator, PORTAL, Harvard Medical School; Brigham & Women’s Hospital, Boston (US)  
CARB-X. Supporting innovation to fight drug-resistant bacteria
Kevin Outterson, Professor & Director of CARB-X, Special CeBIL Advisor, Boston University (US)
Study 2: Orphan Drugs
Introduction to the Orphan Drugs Study
Jakob Wested, Faculty of Law, University of Copenhagen (DK)  
Patients Perspective on Orphan Drug Development
Birthe Byskov Holm, Special CeBIL Advisor, President of the Danish rare disease alliance (Rare Disorders Denmark); EURORDIS, Board of Directors (DK)  
Study 3: Precision Medicine
Introduction to Precision Medicine Study
Glenn Cohen, Professor, Principal Investigator, Petri-Flom Centre Director, Harvard Law School (US)  
Legal Issues Surrounding AIRR-seq Data
Jacob Sherkow, Assoc. Professor, CeBIL Visiting Scholar, New York Law School (US) (with Timo Minssen)  
Panel Debate I
Glenn Cohen (Chair), Aaron S. Kesselheim, Kevin Outterson, Jacob Sherkow, Birthe Byskov Holm, Jakob Wested.
Study 4: New Uses
Old Drugs, New Tricks. Introduction to the New Uses Study
Kathy Liddell, Principal Investigator, Senior Lecturer, Director Centre for Law, Medicine and Life Sciences, University of Cambridge (UK)  
US Perspectives on New Use
Ben Roin, Assistant Professor, Special CeBIL Advisor, MIT Sloan School of Business (US)
Study 5: Drug Manufacturing and Biologics
Innovation in Biopharmaceutical Manufacturing
Nicholson Price, Assistant Professor, Principal Investigator University of Michigan Law School (US)  
"Myriad’s Impact on Gene Patents. Lessons Learned from Empirical Studies”
Mateo Aboy, Professor, Special CeBIL Advisor, University of Cambridge, Oregon Institute of Technology (UK/US)  
Study 6: Synergy & Policy Solutions
Introduction to the Synergy Study
Marcel Bogers, Professor, IFRO, Faculty of Science, University of Copenhagen (DK) (Presented by Timo Minssen)  
The role of management in biomedical innovation
Keyvan Vakili, Ass. Professor, London Business School (UK)  
Panel Debate II
Kathleen Liddell (Chair), Ben Roin, Nicholson Price, Mateo Aboy, Marcel Bogers & Keyvan Vakili  
Quo Vadis CeBIL? The Broader Future & Wrapping Up
Digitalizing the Health & Life Sciences: Emerging Opportunities & Legal Challenges
Timo Minssen, Professor, CeBIL Managing Director, Faculty of Law, University of Copenhagen (DK)  
Life Sciences and Patents in the Fourth Industrial Revolution
Yann Ménière, Professor, Chief Economist at the European Patent Office (EPO), Munich (Ger/Fr)  
Developing better medicine with new collaborations models in the pharmaceutical industry
Niclas Nilsson, Director of Open Innovation, Leo Pharma, An Industry perspective (DK)  
A patient value-based approach to innovation and IP
Elise Melon, Assoc. Director IP Policy Patent Operations Lead at UCB  
Concluding Panel Debate III & Wrapping Up
Timo Minssen (Chair), Esther van Zimmeren, Yann Ménière, Niclas Nilsson & Elise Melon